Berlin, December 6, 2007 – ProBioGen AG, a leading biotechnology company in vertebrate cell engineering and cell culture, today announced the closing of an exclusive licensing agreement for its avian cell line AGE1.CR. The agreement was signed with an undisclosed US vaccine development company and covers a total of four indications, including different forms of influenza and three additional disease areas.
